Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125241151 | 12524115 | 1 | I | 20160620 | 20160704 | 20160704 | EXP | US-ACCORD-041992 | ACCORD | BUHLER AV, HUYNH P, LOW P, VON M. POSSIBLE DRUG-ASSOCIATED SIALOLITHIASIS FROM THE BICARBONATE ANHYDRASE INHIBITOR TOPIRAMATE: A CASE REPORT AND LITERATURE REVIEW. J ORAL MAXILLOFAC SURG. 2016 MAY 20. | 39.00 | YR | F | Y | 0.00000 | 20160704 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125241151 | 12524115 | 1 | PS | TOPIRAMATE. | TOPIRAMATE | 1 | DOSE: FLUCTUATED INITIAL DOSE OF 25 MG TO 100 MG TWICE DAILY. ALSO RECEIVED 50 MG DAILY. | Y | 76311 | 100 | MG | BID | |||||||
| 125241151 | 12524115 | 2 | SS | CALCIUM CARBONATE. | CALCIUM CARBONATE | 1 | Oral | CHEWABLE FORM | U | 0 | 1000 | MG | |||||||
| 125241151 | 12524115 | 3 | SS | MECLIZINE | MECLIZINE HYDROCHLORIDE | 1 | DOSE: 25 MG DAILY AS NEEDED | U | 0 | 25 | MG | ||||||||
| 125241151 | 12524115 | 4 | C | VERAPAMIL | VERAPAMIL HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 125241151 | 12524115 | 5 | C | AMITRIPTYLINE | AMITRIPTYLINE | 1 | 0 | ||||||||||||
| 125241151 | 12524115 | 6 | C | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | 0 | ||||||||||||
| 125241151 | 12524115 | 7 | C | LAMOTRIGINE. | LAMOTRIGINE | 1 | 0 | ||||||||||||
| 125241151 | 12524115 | 8 | C | MEMANTINE HYDROCHLORIDE. | MEMANTINE HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 125241151 | 12524115 | 9 | C | GABAPENTIN. | GABAPENTIN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125241151 | 12524115 | 1 | Hemiplegic migraine |
| 125241151 | 12524115 | 2 | Product used for unknown indication |
| 125241151 | 12524115 | 3 | Vomiting |
| 125241151 | 12524115 | 4 | Hemiplegic migraine |
| 125241151 | 12524115 | 5 | Hemiplegic migraine |
| 125241151 | 12524115 | 6 | Hemiplegic migraine |
| 125241151 | 12524115 | 7 | Hemiplegic migraine |
| 125241151 | 12524115 | 8 | Hemiplegic migraine |
| 125241151 | 12524115 | 9 | Hemiplegic migraine |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125241151 | 12524115 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125241151 | 12524115 | Decreased appetite | |
| 125241151 | 12524115 | Disturbance in attention | |
| 125241151 | 12524115 | Dysgeusia | |
| 125241151 | 12524115 | Gastrooesophageal reflux disease | |
| 125241151 | 12524115 | Memory impairment | |
| 125241151 | 12524115 | Off label use | |
| 125241151 | 12524115 | Paraesthesia | |
| 125241151 | 12524115 | Salivary gland calculus | |
| 125241151 | 12524115 | Sialoadenitis | |
| 125241151 | 12524115 | Urine abnormality | |
| 125241151 | 12524115 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |